Evidence map›Paper›PMID 19411848›Full record

ArticleCell cycle (Georgetown, Tex.)2009

Conserved ATRMec1 phosphorylation-independent activation of Chk1 by single amino acid substitution in the GD domain.

Elizabeth Pereira, Yinhuai Chen, Yolanda Sanchez

Open access · greenAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  2. Article
  3. Regulatory motifs in Chk1.Cell cycle (Georgetown, Tex.) · 2013
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Elizabeth PereiraDepartment of Pharmacology and Toxicology, Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH, USA.
Yinhuai Chen
Yolanda Sanchez
Dartmouth Hospital · GB

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY RESEARCHP30ES006096 · NIEHS · UNIVERSITY OF CINCINNATI · PI YADAV, JAGJIT S · 1992 to 2022
$35.4M
Plk3 variants in transgenic mice and MEFsU01ES011038 · NIEHS · UNIVERSITY OF CINCINNATI · PI STAMBROOK, PETER J. · 2001 to 2006
$6.7M
DISSECTION OF THE DNA DAMAGE CHECKPOINT PATHWAYSR01CA084463 · NCI · UNIVERSITY OF CINCINNATI · PI SANCHEZ, YOLANDA · 2000 to 2009
$2.7M
NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA084463NCI NIH HHS R01 CA84463NIEHS NIH HHS P30 ES006096NIEHS NIH HHS P30 ES06096NIEHS NIH HHS U01 ES011038NIEHS NIH HHS U01 ES11038
6 · The paper itself

Abstract

Chk1 is a conserved kinase that comprises the first line of defense against DNA damage and replication blocks. Chk1 consists of two primary domains, the well conserved N-terminal kinase domain and the non-catalytic C-terminal domain that contains the two highly conserved TRF and GD sub-domains. Several studies suggested that the C-terminus of Chk1 acts as an inhibitory domain and that phosphorylation of the C-terminus by ATR serves to activate Chk1 by relieving the inhibitory effect of the C-terminus on the N-terminal catalytic domain. However, work carried out in many systems showed that phosphorylation on ATR sites was necessary but not sufficient to increase Chk1 kinase activity. In a recent manuscript we described a single amino acid substitution at an invariant Leucine in the conserved GD domain of the yeast Chk1 C-terminus (L506R) that led to a Chk1 protein that no longer required ATR(Mec1) phosphorylation at conserved sites for its function, and relieved the requirement of an upstream mediator, Rad9 (53BP1 homolog), for Chk1 activation. Here we show that this single amino acid substitution in the GD domain also led to constitutive phosphorylation of yeast and human Chk1 on ATR(Mec1) sites, suggesting that the protein was in a conformation in which it could be readily phosphorylated by ATR(Mec1). Unlike the phospho-mimetic mutants in earlier studies, the L505R and L449R modifications led to increased Chk1 activity both in vitro and in vivo. Therefore, we have uncovered a conserved mechanism for Chk1 regulation separate from the role of known ATR phosphorylation sites.

Indexed as

Amino Acid SubstitutionAmino Acid SequenceAtaxia Telangiectasia Mutated ProteinsBinding SitesCatalytic DomainCell Cycle ProteinsCell LineCheckpoint Kinase 1DNA DamageDNA ReplicationHeLa CellsHumansMolecular Sequence DataPhosphorylationProtein KinasesProtein Serine-Threonine KinasesAtaxia Telangiectasia Mutated ProteinsATR protein, humanCell Cycle ProteinsCheckpoint Kinase 1CHEK1 protein, humanProtein KinasesProtein Serine-Threonine Kinasesrad9 protein

Identifiers

PMID19411848
PMCPMC4045630
OpenAlexW2042883687

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.